Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Farallon Capital Management, L.l.c portfolio

Investment firm
Follow Farallon Capital Management, L.l.c
Share

Portfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Farallon Capital Management, L.l.c reported a $16.9 bn portfolio of 80 companies (82 positions, counting each share class separately) to the SEC as of the end of Q2 2026. Its largest positions are RVMD, EA, BBIO. During the quarter it exited Charles Schwab and Alphabet.

Stock portfolio
$16.9 bn
Companies
80
82 positions (by CUSIP)Top 10: 56%
Turnover
25%
Copying its 13F, 5 years
—
Not calculated: not counted as a concentrated manager

Sections with a free account

What it reported after the quarter end (Q2 2026)

The 13F shows the portfolio as of Jun 30, 2026. Since then Farallon Capital Management, L.l.c has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.

  • 13D/AExelixisEXEL5.6 %

    Stake reported in the company · event of Aug 14, 2026 · filed Aug 14, 2026 · filing ↗

  • 13G/AEnanta PharmaceuticalsENTA8.3 %

    Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗

  • 13G/AInflaRxIFRX2.3 %

    Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗

  • 13G/ASavaraSVRA6.8 %

    Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗

  • 13G/ATango TherapeuticsTNGX9.8 %

    Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗

  • 13G/ATyra BiosciencesTYRA0 %

    Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗

  • 13G/ABeta BionicsBBNX1.3 %

    Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗

  • 13G/ABeam TherapeuticsBEAM10 %

    Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗

Plus 10 more, in its EDGAR filings.

What changed this quarter

163 positions with a change (13 new, 28 added to, 22 trimmed, 100 sold); also, 5 entered through an IPO, 4 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).

  • Microsoft−53%fewer sharesReduced5.2% → 2.4%
  • Amazon.com−38%fewer sharesReduced5.2% → 3.7%
  • Aon−45%fewer sharesReduced4.8% → 2.7%
  • Charles Schwab−2.2 ppof portfolioSold out2.2% → —
  • Alphabet−1.7 ppof portfolioSold out1.7% → —
  • Natera−31%fewer sharesReduced3.8% → 3.6%
  • Visa−1.5 ppof portfolioSold out1.5% → —
  • Broadcom−35%fewer sharesReduced3.3% → 2.6%
  • Walt Disney−1.4 ppof portfolioSold out1.4% → —
  • UnitedHealth Group−30%fewer sharesReduced2.9% → 3.1%
  • Mastercard−1.3 ppof portfolioSold out1.3% → —
  • McKESSON−1.2 ppof portfolioSold out1.2% → —

The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.

Top holdings

“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.

Portfolio by sector

  • ● Health Care 70%
  • ● Communication Services 11%
  • ● Information Technology 8%
  • ● Consumer Discretionary 5%
  • ● Financials 5%
  • ● Industrials 1%

How its portfolio changed (8 quarters)

Positions

Q2 2026: 82

1680
Q3 2024Q2 2026
Top 10 weight

Q2 2026: 56%

56%36%
Q3 2024Q2 2026
Traded turnover

Q2 2026: 20.1%

26.9%0
Q3 2024Q2 2026

Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.

13F filings with amendments or confidential positions

Declared options (3)

Besides stocks, Farallon Capital Management, L.l.c declared 2 puts (they gain if the stock falls) and 1 call (they gain if it rises) with a notional of $4.6 bn. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.

Stakes above 5% (13D/13G)

Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.

How we classify it

Investment firm, per its Form ADV of Sep 23, 2026 (high confidence).

The data, as reported: FARALLON CAPITAL MANAGEMENT, L.L.C. (CRD 107322): 7.B private funds: 50 hedge (gross assets $64.5 bn); 5.D assets by client type: pooled vehicles 100% (of $52.1 bn)

The type comes from a rule applied to that data. If it looks wrong, tell us.

Not counted as a concentrated manager: more than 20% is options. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided

Similar managers by type and size

Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.

Follow Farallon Capital Management, L.l.c for free

When the next 13F is filed, we email you (if you turn it on) and it shows in your list. No credit card.

Follow Farallon Capital Management, L.l.c